Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant virus-like particle seasonal influenza vaccine
- Development stage
- Approved
- Lead developer
- Novavax
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Intranasal, Subcutaneous, Transdermal
01
Overview
The recombinant virus-like particle seasonal influenza vaccine is a vaccine developed by Novavax. It utilizes Novavax’s proprietary recombinant cell-culture technology and virus-like particle (VLP) platform to target seasonal influenza. The vaccine is designed to elicit an immune response against the influenza virus by presenting virus-like particles that mimic the structure of the virus but are non-infectious. This development was supported by a contract from the Biomedical Advanced Research and Development Authority (BARDA) as part of U.S. government pandemic preparedness initiatives to create faster, scalable, and more flexible vaccine manufacturing capabilities.
- Other names
- trivalent VLP influenza vaccine
Beyond the preview
Go deeper on recombinant virus-like particle seasonal influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant virus-like particle seasonal influenza vaccine.